You are here
Home 🌿 Medical Cannabis News 🌿 THC’s Canndeo gets green light to manufacture medicinal cannabis extracts 🌿THC’s Canndeo gets green light to manufacture medicinal cannabis extracts
THC Global’s (ASX: THC) wholly-owned subsidiary Canndeo has achieved a major milestone by securing a manufacturing licence to produce cannabis extracts and tinctures in Australia.
The Australian Office of Drug Control granted the licence to Canndeo, which now completes THC’s vertical integration strategy to cultivate its own cannabis strains, harvest and process the material to produce its own cannabis-based products for Australian and international markets.
“We are very pleased to be granted a manufacture licence, which now completes our ‘farm to pharma’ model,” THC chairman Steven Xu said.
“This licence is a significant milestone for the company, with the next targets being the development of a new generation of proprietary medicinal cannabis products and securing our revenue outlook through offtake agreements and furthering our existing global partnerships,” Mr Xu added.
THC’s global growth plans
Via its subsidiaries, THC now holds the three key cannabis licences in Australia that allow it to research, cultivate and manufacture medicinal cannabis products in the country.
Additionally, THC has firmed up “significant cannabis growing capacity” via multiple cultivation projects, with 60,000 square metres of leased land subject to a cultivation permit.
THC also has an agreement with EVE Investments (ASX: EVE) to lease additional land bringing its cultivation site potential in northern New South Wales up to 150,000sq m.
In readiness of manufacturing medicinal cannabis products, THC owns a pharmaceuticals bio-manufacturing facility with an attached testing and product development laboratory.
As well as serving Australian medicinal cannabis demand, THC plans to sell its products into Canada, Europe, Asia and the Middle East through either local operations or partnerships.
THC has a strong presence in Canada including a property in Nova Scotia currently being developed into a large scale cannabis production site.
The company secured the site in March this year, with first stage development estimated to yield 37,000kg of dried flower annually.
THC’s share price shot up more than 13% on the manufacturing licence news to sit at $0.50 by mid-morning.
420 Intel is Your Source for Marijuana News
420 Intel Canada is your leading news source for the Canadian cannabis industry. Get the latest updates on Canadian cannabis stocks and developments on how Canada continues to be a major player in the worldwide recreational and medical cannabis industry.
420 Intel Canada is the Canadian Industry news outlet that will keep you updated on how these Canadian developments in recreational and medical marijuana will impact the country and the world. Our commitment is to bring you the most important cannabis news stories from across Canada every day of the week.
Marijuana industry news is a constant endeavor with new developments each day. For marijuana news across the True North, 420 Intel Canada promises to bring you quality, Canadian, cannabis industry news.
You can get 420 Intel news delivered directly to your inbox by signing up for our daily marijuana news, ensuring you’re always kept up to date on the ever-changing cannabis industry. To stay even better informed about marijuana legalization news follow us on Twitter, Facebook and LinkedIn.